

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 September 2023 (14.09.2023)



(10) International Publication Number
WO 2023/172685 A1

(51) International Patent Classification:

A61K 31/5517 (2006.01) A61P 25/08 (2006.01)

(21) International Application Number:

PCT/US2023/014908

(22) International Filing Date:

09 March 2023 (09.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

Published:

— with international search report (Art. 21(3))

(30) Priority Data:

63/318,670 10 March 2022 (10.03.2022) US

(71) Applicant: ARENA PHARMACEUTICALS, INC.

[US/US]; 235 East 42nd St., New York, New York 10017 (US).

(72) Inventors: PARASRAMPURIA, Dolly; 1636 Tucker-

stown Road, Dresher, Pennsylvania 19025 (US). OREVIL-
LO, Chadwick J.; 12 Glencrea Lane, Lebanon, New Jersey
08833 (US). PERERA, Philip; 30883 North Glory Grove,
Sun Tan Valley, Arizona 85143 (US).

(74) Agent: DYAR, Scott et al.; P.O. Box 1022, Minneapolis,

55440-1022 (US).


(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,

(54) Title: METHODS OF TREATMENT



(1)

(57) Abstract: Provided is a method of treatment of a 5-hydroxytryptamine (HT)_{2C} receptor-associated disorder comprising: prescribing and/or administering to an individual in need thereof, (R)-N-(2,2-difluoroethyl)-7-methyl-1,2,3,4,6,7-hexahydro-[1,4]diazepino[6,7,1-hi]indole-8-carboxamide (Compound (1)), or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

WO 2023/172685 A1